Intratumoral Injection of Autologous CD1c (BDCA-1)+ myDC, Avelumab, and Ipilimumab Plus Systemic Nivolumab
Status:
Completed
Trial end date:
2020-12-24
Target enrollment:
Participant gender:
Summary
This phase I trial aims at investigating a new combinatorial immunotherapy regimen using
intratumoral injection of autologous CD1c (BDCA-1)+ myeloid dendritic cells in combination
with intratumoral injection of the CTLA-4 blocking monoclonal antibody (mAb) ipilimumab and
the PD-L1 blocking mAb avelumab. Concomitantly, nivolumab (a PD-1 blocking mAb) will be
administered intravenously.